Advancing Endotoxin Testing with Recombinant Technology:Understanding USP <86>
BETMAT Biotechnology is committed to advancing bacterial endotoxin testing (BET) through innovative, animal-free technologies that meet the highest global standards of safety and scientific integrity. The publication of the United States Pharmacopeia (USP) Chapter <86>, “Bacterial Endotoxins Test Using Recombinant Reagents”, marks a significant step forward in the modernization of endotoxin testing methodologies. This chapter formally recognizes recombinant reagents—Recombinant Factor C (rFC) and Recombinant Cascade Reagents (rCR)—as validated, science-based alternatives to the traditional Limulus Amebocyte Lysate (LAL) assays derived from horseshoe crabs.
The Purpose and Background of Chapter <86>
USP <86> provides additional and complementary methods to the long-established Bacterial Endotoxins Test <85>. While <85> describes the use of LAL reagents derived from horseshoe crab blood cells, the new chapter introduces non-animal-derived recombinant methods for detecting and quantifying endotoxin activity. These assays replicate the natural biochemical cascade of the Limulus clotting pathway using cloned recombinant zymogens—either a single Factor C (rFC) or a complete cascade of Factors C, B, and pro-clotting enzyme (rCR).
The USP Microbiology Expert Committee, which includes representatives from the FDA and global regulatory authorities, reviewed extensive scientific data from published studies, stakeholder submissions, and USP-generated experiments before finalizing the proposal. The chapter aligns with USP’s broader commitment to reduce animal use in quality control testing without compromising accuracy, sensitivity, or regulatory reliability.
Key Regulatory Perspective
Importantly, USP <86> does not replace LAL-based testing. Instead, it offers manufacturers an optional, scientifically validated route to use animal-free reagents. Companies already employing LAL may continue without disruption, while those developing new biopharmaceutical products can directly implement rFC or rCR methods without the need for comparability testing against LAL. For existing products, a demonstration of method equivalence is typically required, following established validation practices.
Regulatory authorities—including the FDA, EMA, and PMDA—recognize these recombinant approaches, though they may request supplemental validation data, such as side-by-side comparisons with LAL methods. The procedures outlined in USP <86> clearly define the expectations for demonstrating fitness-for-use, ensuring that recombinant assays meet or exceed the analytical performance of traditional LAL tests in terms of accuracy, precision, sensitivity, and specificity.
Global Harmonization and Industry Alignment
USP <86> aligns closely with the European Pharmacopeia and Japanese Pharmacopeia, which have already introduced chapters supporting recombinant Factor C methods. The USP proposal extends this by formally incorporating Recombinant Cascade Reagents (rCR), reflecting their increasing commercial availability and scientific validation. Efforts are underway to harmonize these standards across major pharmacopeias, enabling consistent regulatory acceptance worldwide.
The Role of BETMAT Biotechnology LLC
As the professional manufacturers in endotoxin detection innovation, BETMAT Biotechnology LLC actively supports the transition toward sustainable, high-performance testing solutions. BETMAT’s portfolio of recombinant endotoxin detection reagents is engineered to deliver equivalent or superior analytical reliability compared with LAL assays—while eliminating the ecological impact associated with horseshoe crab harvesting.
Our rFC and rCR assay kits are optimized for compatibility with standard endotoxin detection instruments, offering precise quantification, minimal interference, and streamlined laboratory workflows. By adopting BETMAT’s recombinant platforms, pharmaceutical and biotechnological manufacturers can ensure regulatory compliance, enhance sustainability, and uphold the highest standards of product safety.
Looking Ahead
The implementation of USP <86> marks a pivotal advancement in global quality control practices. Recombinant BET methods represent the future of ethical, reliable, and sustainable endotoxin detection—providing a pathway for innovation that aligns scientific excellence with environmental responsibility.
At BETMAT Biotechnology LLC, we are proud to contribute to this evolution through ongoing research, expert support, and cutting-edge assay development—empowering our partners worldwide to embrace next-generation bacterial endotoxin testing.